Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | PGA5 | P0DJD9 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CTSE | P14091 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | CCKAR | P32238 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6702703 | 1.00 | MLNR (0.39) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL7406895 | 0.93 | ALDH1A1 (0.40) | GAAL3MBTL1ALDH1A1BACE1HSD11B1 | |
| SCHEMBL6174625 | 0.88 | MMP2 (0.35) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL6953138 | 0.87 | HPGD (0.35) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL8340516 | 0.86 | ALDH1A1 (0.37) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL8014766 | 0.86 | ALDH1A1 (0.37) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL13550979 | 0.86 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL6172742 | 0.85 | GAA (0.37) | GAAL3MBTL1ALDH1A1BACE1PRKCA | |
| SCHEMBL7890688 | 0.84 | NPC1 (0.38) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL8014541 | 0.83 | LTA4H (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368331-A1 | CONTINUOUS METHOD FOR PRODUCING DIHYDROPYRONES | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-12-10 | — | — | EP | claimed |
| WO-2002068403-A1 | CONTINUOUS METHOD FOR PRODUCING DIHYDROPYRONES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-06 | — | — | WO | claimed |
| WO-2006128590-A1 | HYDROLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | DSM IP ASSETS B.V. (NL) | 2006-12-07 | — | — | WO | disclosed |
| US-7141681-B2 | Continuous process for preparing dihydropyrones | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-11-28 | — | — | US | disclosed |
| WO-2006006851-A2 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY ENRICHED ESTER OR THE CORRESPONDING ACID THEREOF | DSM IP ASSETS B.V. (NL) | 2006-01-19 | — | — | WO | disclosed |
| EP-1203770-B1 | Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hyperplasia and other diseases | UPJOHN CO (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | disclosed |
| EP-1368331-A1 | CONTINUOUS METHOD FOR PRODUCING DIHYDROPYRONES | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-12-10 | — | — | EP | disclosed |
| EP-0758327-B1 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | UPJOHN CO (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20020161037-A1 | Continuous process for preparing dihydropyrones | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-31 | — | — | US | disclosed |
| EP-0668860-B1 | PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES | UPJOHN CO (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2002068403-A1 | CONTINUOUS METHOD FOR PRODUCING DIHYDROPYRONES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-06 | — | — | WO | disclosed |
| EP-1203770-A1 | Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hyperplasia and other diseases | PHARMACIA & UPJOHN COMPANY (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6169181-B1 | HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2001-01-02 | — | — | US | disclosed |
| US-5852195-A | Pyranone compounds useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0758327-A1 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995030670-A2 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-16 | — | — | WO | disclosed |
| EP-0668860-A1 | PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES | PHARMACIA & UPJOHN COMPANY (US) | 1995-08-30 | — | — | EP | disclosed |
| WO-1994011361-A1 | PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES | THE UPJOHN COMPANY (US) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161037-A1 | Continuous process for preparing dihydropyrones | CYP2F1, CYP2D6, SDHA | MLNR 3391/4885NR1I2 560/4885ABCB11 633/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | MLNR 3788/4885NR1I2 2278/4885ABCB11 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.